Mesoblast Total Long Term Liabilities 2012-2023 | MESO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Mesoblast total long term liabilities from 2012 to 2023. Total long term liabilities can be defined as the sum of all non-current liabilities.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Mesoblast total long term liabilities from 2012 to 2023. Total long term liabilities can be defined as the sum of all non-current liabilities.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$231.2B
Amgen (AMGN)	$160B
Gilead Sciences (GILD)	$137.1B
Vertex Pharmaceuticals (VRTX)	$123.3B
Bristol Myers Squibb (BMY)	$113.2B
CSL (CSLLY)	$80.1B
GSK (GSK)	$76.6B
Regeneron Pharmaceuticals (REGN)	$76.1B
Argenex SE (ARGX)	$39.3B
Alnylam Pharmaceuticals (ALNY)	$32.5B
BioNTech SE (BNTX)	$28.3B
BeiGene (ONC)	$23.9B
Biogen (BIIB)	$20.1B
Illumina (ILMN)	$15.4B
Insmed (INSM)	$15B
Genmab (GMAB)	$14.9B
Genmab (GNMSF)	$14.7B
Incyte (INCY)	$13.8B
Intra-Cellular Therapies (ITCI)	$13.7B
BioMarin Pharmaceutical (BMRN)	$13.1B
Moderna (MRNA)	$13B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
Sarepta Therapeutics (SRPT)	$10.4B
Bio-Techne Corp (TECH)	$10.4B
Vaxcyte (PCVX)	$10.3B
Exelixis (EXEL)	$9.8B
Ascendis Pharma (ASND)	$9.4B
Exact Sciences (EXAS)	$9.2B
Repligen (RGEN)	$9.1B
Bio-Rad Laboratories (BIO.B)	$8.7B